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Erythrocyte repopulation after major ABO incompatible 
transplantation with lymphocyte-depleted bone marrow
BMAM Bar1, BA Van Dijk2, A Schattenberg1, AJM de Man2, VAJM Kunst1 and T de Witte1
Summary: Buckner et ciP have demonstrated that major ABO incom­
patibility is no obstacle to succcessful outcome after BMT.
Forty-four out of 258 allogeneic BMT were performed No increased risk of graft rejection, graft-versus-host dis-
across the major ABO barrier. Donor erythrocyte ease (GVHD) or mortality related to ABO incompatibility
repopulation could be evaluated in 30 cases. Fifty-eight have been observed. Several reports have described delayed
patients transplanted with an ABO compatible or minor hemolytic anemia, delayed onset of erythropoiesis, pure red
incompatible graft served as the control group. All pati- cell aplasia (PRCA) and increased post-transplant trans-
ents received a marrow graft depleted of lymphocytes 
by counterflow centrifugation. Less than 108 residual 
erythrocytes were present in the graft. Cyclosporin A
fusion requirements
BMT.8- 13
after major ABO incompatible
In contrast to the previous studies all patients trans-
was used as immunoprophylaxis after transplantation. planted in our center received marrow grafts depleted of
Erythrocyte repopulation was measured using a fluor- lymphocytes by élutriation. Donor erythropoiesis and trans-
escent microsphere method. An adapted transfusion fusion requirements were evaluated in 30 patients who
policy was applied. Eight out of 30 patients (27%) with received a major ABO incompatible graft and compared to
major ABO incompatibility had no detectable donor an ABO compatible or minor ABO incompatible control
erythrocytes 2 months after BMT. Up to 3 months after group of 58 patients. Delayed onset of erythropoiesis
BMT donor erythrocyte repopulation was significantly occurred in eight patients who received a major ABO
delayed in the ABO incompatible group (P ^  0.03). Sig- incompatible graft. The clinical course after BMT of these
nificantly more erythrocyte transfusions were required patients is described in more detail. The pretransplant titers
in the ABO incompatible group (P <  0.001). Six patients and the post-transplant course of ABO antibodies in these
with blood group O (20%) developed pure red cell apla- patients were compared to those of the other 22 patients
sia which resolved in five without therapeutic inter- transplanted with a major ABO incompatible graft, 
vention. In these six patients anti-A antibody titers were 
persistently high the first 3 months after BMT. This was
in contrast with 22 patients with timely recovery of 
erythropoiesis in whom anti-A and anti-B antibody tit­
ers showed a steady decrease after BMT. The incidence 
of immunohematological complications in these patients
Subjects and methods
Patient groups
who received a lymphocyte depleted major ABO incom- From 1981 to 1994, 285 allogeneic bone marrow transplan-
patible graft is similar (20%) to the incidence reported tations were performed in adults. In 44 cases (15%) major
in the literature. Serious morbidity related to m ajor ABO incompatibility existed between patient and donor. In
ABO incompatibility did not occur. 14 out of 44 patients donor erythrocyte repopulation could
Keywords: erythrocyte repopulation; ABO incompati- not be evaluated for the following reasons; early transplant-
bility; lymphocyte depleted; BMT
Major ABO incompatibility between recipient and donor
related mortality within 1 month after BMT in three, early 
relapse within 6 months after BMT in live, graft failure and 
autologous recovery in three and no available data in three 
patients. The remaining 30 patients were transplanted for 
acute myeloid leukemia (AML) (n = 6), acute lymphoid
occurs in about 10-15% of HLA matched allogeneic bone leukemia (ALL) (n = 8), chronic myeloid leukemia (CML)
marrow transplantations. Acute sis by anti-A or
anti-B antibodies of recipient origin at the time of infusion 
of the donor marrow can be prevented by reduction of the
(n -  14), severe aplastic anemia (SAA) (n= 1) and eosino­
philic syndrome (n = 1). Twenty patients with blood group 
O received either a blood group A graft {n = 19) or a blood
antibody titers in the recipient or by removal of erythro- group g graft (n = i). AB marrow was transplanted to three
cytes from the graft.1*5 Studies by Bensinger et a t  and
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patients with blood group A and one patient with blood 
group B. Three patients with blood group A received a 
blood group B graft and three patients with blood group B 
received a blood group A graft.
Twenty-six donors were HLA-identical sibling donors 
and four donors were HLA-matched unrelated volunteers
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(UPN 168, 199, 226 and 281). Conditioning regimens (0.01%).20 Donor erythrocyte repopulation was studied at
always included cyclophosphamide (CY) in a total dose of 0.5, 1, 2, 3, and 6 months after BMT.
120 mg/kg. This was followed by total body irradiation
(TBI) in two equal fractions with 24 h interval in a total Ajjf; A m d  anfi_B antibodies
or 9 or 12 Gy in 28 patients. Anthracyclmes
(daunorubicin 156 mg/m2 or demethoxydaunorubicin Anti-A and anti-B agglutinin (IgM) titers were determined
42 mg/m2) were added in 18 out of 22 patients who by incubating a 3% standard A and B erythrocyte suspen-
received TBI in a dose of 9 Gy. One patient (UPN 281) sion in saline with 2-fold serial dilutions of patient serum
was conditioned with CY, TBI (9 Gy) and total lymphoid at 37° C for 45 min followed by centrifugation and scoring
irradiation (TLI) (8 Gy). Another patient was treated with for macroscopic agglutination. Anti-A and anti-B IgG titers
busulphan and CY (UPN 126). In the only patient (UPN were measured by pretreating the patient serum with dithio-
226) transplanted for SAA the conditioning regimen con- treitol at 37° C for 45 min followed by indirect antiglobulin
sisted of CY and TLI (12 Gy). Details on the conditioning testing with anti IgG serum and scoring for macroscopic
regimens have been described ear lier.'4’15 Plasma exchange agglutination.
or plasma immunoadsorption to reduce anti-A or anti-B 
antibody titers before BMT were never applied.
In the same time period, 241 ABO compatible or minor 
ABO incompatible transplantations were performed. Fifty- 
eight patients could be used as a control group to study
Antibody titers were determined before and at least 0.5, 
1, 2, 3 and 6 months after BMT.
Statistical analysis
donor erythrocyte repopulation. The remaining patients The Fisher’s exact test was used to compare clinical vari-
were considered not to be evaluable mainly because of lack ables between groups. The Kruskal-Wallis test was applied
of a donor erythrocyte marker (see below) or because they to compare percentages of donor erythrocytes at different
received unselected transfusions not taking into account the time points after BMT. Within the study group antibody
donor marker. Other reasons were early transplant-related titers were compared using the Mann-Whitney U test.
mortality, early relapse or graft failure. Indications for 
transplantation were AML (n = 14), ALL (n = 15), CML 
(71=17), low-grade non-Hodgkin lymphoma (n = 5), mul­
tiple myeloma {n = 4), SAA (n = 2), and myeloproliferative
Results
syndrome (n — 1). Fifty-four donors were genotypically Recovery o f erythropoiesis in the study and control group
Because of reasons mentioned earlier it was not possibleHLA-identical sibling donors and four donors were one locus mismatched siblings. The conditioning regimens 
always included CY (120 mg/kg). Except for one patient 
who was treated with TLI, all patients received TBI in a 
total dose of 9 or 12 Gy. Anthracyclines were added in 35 
out of 39 patients treated with TBI in a dose of 9 Gy.
Both in the study and in the control group all marrow 
grafts were depleted of lymphocytes by density gradient 
centrifugation followed by counterflow centrifugation.16
to form a fully matched control group based on matching 
for indication for BMT, conditioning regimen, age and 
acute GVHD. Table 1 shows the comparison of clinical
Table 1
trol group
Comparison of clinical data between the study and the con-
10 residual erythrocytes were present in the 
marrow graft. Cyclosporin A (CsA) was used as immuno- 
prophylaxis post-transplant in all patients in a schedule, as 
previously described.17
ocvte
Analysis of patient and donor erythrocyte populations in 
the first months after BMT required an adapted transfusion 
policy.18,19 Before BMT, preferentially before any trans­
fusions were given, a sample for complete red cell pheno- 
typing was drawn from the patient. After phenotyping of 
the donor, marker antigens, ie antigens present in the donor 
and absent in the recipient and vice versa, were determined. 
In case of major ABO incompatibility the A or B antigen 
was used as a donor marker. In the control group donor 
marker antigens were C, c, D, E, K, M, N, S, s, Fya, Fyb, 
Jka, Jkb and Kpa. Erythrocyte transfusions of blood group 
O lacking the marker antigens were administered to all pati­
ents in both groups.
Measurement of host and donor populations was perfor­
med by a fluorescent microsphere method. The sensitivity 
of this assay is one positive cell per 10000 negative cells
Major ABO 
incompatible BMT
n = 30
Control group
n = 58
Conditioning regimen
TBI 9 Gy 22 39
12 Gy 6 18 NS
Anthracyclines (added
to TBI 9 Gy) 18 35 NS
Indications for BMT
Acute leukemia 14 29
CML 14 17
Others 2 12 NS
Age (years)
<  40 21 30
5= 40 9 28 NS
Donors
Histocompatible
sibling 26 54
Others 4 4 NS
GVHD (grade)
0-1 23 41
5= 11 7 17 NS
No significant differences of clinical variables between the groups were 
found (Fisher’s exact test)
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variables between the two groups. No significant differ­
ences could be found.
BMT. Treatment consisted of addition of 
corticosteroids to the CsA. While tapering off these drugs
Table 2 shows the means and standard deviations of per- she developed limited chronic GVHD of the gut. Two
centages of donor erythrocytes at various time points after months after BMT a bone marrow aspirate showed active
BMT. Significant delay in donor erythrocyte repopulation myelopoiesis, absent erythropoiesis and no megakaryo-
in the ABO incompatible patient group compared to the cytes. Three months after BMT the percentage of donor
control group could be demonstrated up to 3 months after erythrocytes was 0.22. At that time point erythropoiesis in
BMT. The difference between the two groups was no the marrow was active but the number of megakaryocytes
longer significant at 6 months after BMT. was still low. She remained erythrocyte transfusion depen-
To demonstrate delayed donor erythrocyte repopulation dent with 0.07% of donor erythrocytes 4 months after
in the major ABO incompatible group we compared the BMT. Platelet counts never rose above 50 x 1071. She died
relative number of patients without detectable donor eryth- of CMV pneumonitis 6 months after BMT. 
rocytes (ie <  0.01%) between both groups at various time UPN 100 remained transfusion dependent up to 3 months 
after BMT. During this period there were no signs of acute
GVHD.
points early after BMT. In the study group 62% and 33%
of the evaluable patients had no donor red cells detectable  Bone marrow morphology at 1 and 3 months 
at 0.5 and 1 month after BMT, respectively. In the control showed PRCA. At 3 months after BMT no donor erythro- 
group
( P < 0 . 0 1 ) .
percentages were 19% and 0% respectively cyte percentage was available. At 3.5 and 4 months after
BMT these percentages were 4.2 and 19.2, respectively. He
The median number of erythrocyte transfusions is in remission of ALL with 100% donor erythrocytes and
BMT was 18 (range 6-64) in the ABO incompatible group no recipient erythrocytes at 6.5 years after BMT.
and 10 (range 2-46) in the control group (P < 0.001). 
Leukocyte and platelet recovery did not differ between
UPN 70 had no detectable donor erythrocytes up to 3 
months after BMT with the picture of PRCA in the marrow
the ABO incompatible group and the control group (data aspirate. The patient did not suffer from acute GVHD.
not shown).
Delayed onset of erythropoiesis of at least 2 months after 
BMT
Eight patients in the ABO incompatible group (recipients 
blood group O, grafts blood group A) had no detectable 
donor erythrocytes up to 2 months after BMT (UPN 70,
Treatment with corticosteroids was started 4.5 months after 
BMT in an attempt to stimulate donor erythropoiesis. One 
month later the percentage of donor erythrocytes was 36 
and this gradually increased to 100% afterwards. This pati­
ent is in complete hematological, cytogenetic and molecular 
remission of CML 7 years after BMT.
UPN 126 had no detectable donor red cells up to 6 
months after BMT reflected by PRCA in the marrow aspir-
83, 100, 126, 162, 199, 253, 281). In this same time period ates performed 1, 3 and 6 months after BMT. Cytogenetic
percentages of recipient erythrocytes in the six out of eight analysis of the bone marrow performed 6 months after
patients with a recipient marker (UPN 83 and 281 had no BMT showed only cells of donor origin. Neither acute nor
recipient marker) were progressively decreasing. In these chronic GVHD occurred. The last erythrocyte transfusion
eight patients leukocyte counts >  1.0 x 1071 were reached was required 6.5 months after BMT. Nine months after
at a median of 29 days after BMT (ranging from 19 to 35 BMT, 78% donor erythrocytes were present. This patient
days). Patient UPN 199 died of cerebral haemorrhage while died of marrow and CNS relapse of AML 10 months after
hypertensive due to CsA intoxication. At the time of death, 
2 months after BMT, the platelet count was still below 
20 x 10'VI. In the remaining patients a platelet concentration 
of >  20 x 1071 without transfusion support was reached at 
a median of 21 days with a range of 18 to 116 days. Data 
on these patients are given in Table 3.
UPN 83 developed grade 2 acute GHVD of the skin 3
BMT while only donor, but no recipient, red cells could 
be demonstrated.
UPN 162 had PRCA in the marrow aspirate and no
; donor erythrocytes 3 months after BTM. In these 
he was treated with corticosteroids for acute 
GVHD grade I limited to the skin. From 4 months onwards 
the percentage of donor cells started to rise to 100% at I 
year after BMT. Cytogenetic relapse of CML occurred 1
Table 2
1/>
(months)
Donor erythrocytes repopulation in time
Major ABO 
incompatible BMT 
% donor ervthrocvtes
Control group 
% donor erythrocytes
• -
“Number of evaluations. 
hStandard deviation
P value
1 <>. t  •  r »  » ♦ * » »  ^  • •  <.■* u w  «  ?  y  '
n" Mean s.cl.b n“ Mean s. cl.b
J  J «  • -  ft. 1 *  y  J .T Ì .1 .Ì  < CY ‘  « ^  H A - i l i * *  t * *  a  .  • *  ■
0.5 26 0.04 0.07 54 0.23 0.56 <0.0 1
1 30 1.73 2.66 54 5.26 4.81 <0.01
2 27 18.02 20.47 50 29.64 14.76 <0.01
3 25 38.65 32.25 51 55.93 22.02 0.03
6 25 73.93 31.29 51 83.93 18.69 0.2
year
UPN 253, transplanted for ilic syndrome, had
no detectable donor erythrocytes until 6 months after BMT 
at which time point the percentage was 2 and erythropoiesis 
could for the first time be observed in the marrow aspirate. 
Acute GVHD did not occur. He died of Aspergillus sepsis
de novo chronic GVHD of the liver 9.5
months after BMT.
In UPN 281, transplanted with an unrelated graft for 
CML in first accelerated phase, donor erythrocytes were 
never demonstrable during follow-up. She developed acute 
GVHD grade I limited to the skin which was successfully 
treated by addition of corticosteroids to the CsA. Because 
of limited chronic GVHD of the skin and gut, treatment 
with low-dose CsA was continued. Bone marrow mor-
796
Major ABO Incompatible Lymphocyte-Depleted BMT
BMAM Bër et al
Table 3 Data on 30 major ABO incompatible patients
UPN Pretransplant anti-A or Leukocytes"
anti-B titers > 1.0 x 1QVI
IgM IgG
Delayed onset o f erythropoiesis (n = 8)
70 32 512 30
83 256 512 33
100 32 128 19
126 512 16000 21
162 64 64 30
199 128 1 024 35
253 32 128 28
281 64 2048 22
Median 64 512 29
Timely onset o f erythropoiesis (n = 22)
Median 64 16 20
range 4—512 1-512 10-29
“Days after BMT. 
bMonths after BMT. 
cUntil death.
NE = not evaluable, patient died 2 months after BMT
Platelets^ Time to onset of Erythrocyte
> 20 x 1 Cr/I erythropoiesisb transfusions (no.)
19 5.5 36
116 3 42°
23 3.5 15
18 7 37
21 4 29
— NE 28u
19 6 49
27 >9 64c
21 5.5 37
25 1 16
11-50 0.5-2 6-30
phology at 6 and 9 months after BMT showed PRCA. Cyto- were significantly different (P <  0.01) between the groups, 
genetic and molecular remission existed at these obser- This difference still existed after leaving out the IgG titer
vation points. In situ hybridization showed only donor cells. 
Relapse with blast crisis occurred 11 months after BMT. 
The patient died 1 month later.
of 16000 of UPN 126 OP = 0.01).
In the 22 patients mentioned above, a sharp decrease of 
anti-A and anti-B antibodies IgM as well as IgG, was 
All eight patients with delayed onset of erythropoiesis observed after BMT. Three months after BMT IgM and 
had blood group O in contrast to 12 out of 22 patients in IgG titers were measured in 20 out of 22 patients. At that 
the major ABO incompatible group with timely onset of time point the IgM titer was zero in 14 patients and varied
erythropoiesis (P = 0.02).
Course o f recipient erythrocytes in the study and control 
group
The course of recipient erythrocytes after BMT could be
from one to eight in the remaining six patients. The IgG 
titer was zero in 11 patients and varied from one to eight 
in the other nine patients. The mean antibody titers (IgM 
and IgG) of the 22 patients before and in the first 6 months 
after BMT are shown in Figure la and b.
The course of the anti-A and anti-B antibodies after BMT
studied in 20 patients in the study group and 36 patients in in the eight patients with delayed onset of donor erythropoi-
the control group. The same rates of decreasing percentages esis is also shown in Figure la (IgM) and b (IgG). Within
of recipient erythrocytes were observed in the control group the first month after BMT an increase of titers was observed 
and in the study group, both in patients with delayed and in some patients and stable titers in other patients. Only
in patients with timely recovery of donor erythropoiesis. UPN 83 showed a three-step decrease of titers in this time
Six months after BMT, recipient erythrocytes were still period. Three months after BMT all seven patients still 
detectable in eight out of 17 patients in the study group alive had detectable antibody titers in a range higher than 
and nine out of 32 patients in the control group (P = 0.1). the other 22 patients in the ABO incompatible group.
At that time point means and standard deviations of per­
centages of recipient erythrocytes were 0.23 ± 0.2 and 
0.48 ± 0.47 for the study and the control group respectively Discussion 
(not significantly different). This data implicates a high per­
centage of mixed erythrocyte chimerism in both the major Delayed onset of donor erythropoiesis and persistence of
ABO incompatible and the control group.
Anti-A and anti-B antibody titers in major ABO 
incompatible BMT
anti-A or anti-B hemagglutinins are well known phenom­
ena after major ABO incompatible BMT.5,9’10 After red cell 
depletion of the graft Sniecinski et al9 observed delayed
onset of erythropoiesis >  40 days after BMT and persist­
ence of anti-A and anti-B antibodies >  120 days in 10 out
Anti-A and anti-B titers before BMT were compared of 66 (15%) major ABO incompatible transplantations. In
between the eight patients with delayed onset of donor a later study on major ABO incompatibility these compli-
erythropoiesis and the remaining 22 patients in the major cations occurred in nine out of 58 (16%) patients while the
ABO incompatible group (Table 3). No significant differ- overall incidence of immunohematological complications
ence in saline (IgM) titers before BMT could be observed was 21%. Serious associated morbidity was not observed
between the two groups. However, IgG titers before BMT however and erythropoiesis became normal in all but one
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donor erythrocytes 3 months after BMT. Major ABO 
incompatibility may have played a role in the delayed onset 
of erythropoiesis in this patient but GVHD and recurrent 
viral infections can not be ruled out as additional causa­
tive factors.
All patients with delayed onset of donor erythropoiesis 
were blood group O which was significantly more often 
than in the major ABO incompatible patients with timely 
onset of erythropoiesis. Most cases of PRCA after BMT 
reported in the literature involve patients with blood group 
O and donors with blood group A or B, although two cases 
of a recipient with blood group A and a donor with blood 
group B and vice versa have been described.10,11’21,22
Twenty-two patients in the major ABO incompatible 
group had detectable donor erythrocytes within 2 months 
after BMT. Pretransplant IgM anti-A and anti-B antibody 
titers were identical and IgG titers were significantly lower 
compared to the eight patients with delayed onset of 
erythropoiesis. Various reports in the literature did not 
agree on a correlation between pretransplant ABO antibody 
titers and the number of days post-transplant before onset 
of erythropoiesis.5,10,11
In the 22 patients antibody titers decreased immediately
BMT
BMT
before 1 2 3 4 5 6
Time (months)
of Gmtir et all[ in 11 patients with timely recovery of 
erythropoiesis after major ABO incompatible BMT. They 
described a progressive decrease and titers persistently 
16 from day 32 onward. The course of ABO antibodies 
after BMT was clearly different in seven out of eight pati­
ents in our study with delayed onset of erythropoiesis. An 
early rise or persisting high titers (IgG more than IgM) were 
observed in this group. A correlation between delayed onset 
of erythropoiesis and post-transplant rise or persistence of 
high (above 16) antibody titers was also described in recipi­
ents of a non-lymphocyte-depleted major ABO incompat­
ible graft. Only after a substantial reduction in these titers 
to a level of four to 16 erythrocyte production began.5,10,11 
Delay in erythropoiesis can be explained by the interaction 
of anti-A or anti-B antibodies with donor erythroid precur­
sors expressing the A and/or B antigens.23,24
A study comparing the course of anti-donor ABO anti­
bodies after BMT between recipients of elutriated and non­
elutriated major ABO incompatible grafts was performed 
by Bar et a l2s Although the number of patients studied was 
small, no evidence for prolonged persistence of anti-donor 
antibodies in the elutriated group was found.
The incidence of immunohematologic complications and 
ABO incompatible transplants (20%) developed PRCA PRCA (20%) in our study is similar to the incidence 
lasting 5 to 8 months. In our study erythropoiesis was reported in the literature.10,11 Theoretically one could have 
delayed in the 30 patients who received a major ABO expected a higher incidence of immunohematological corn- 
incompatible graft compared to an ABO compatible or plications in our patients. Firstly, all our patients received 
minor ABO incompatible control group. In eight out of 30 red cell depleted grafts instead of lowering pretransplant
■ UPN 70 
+ UPN 83 
O UPN 100
□  UPN 126 
x UPN 162 
O UPN 199
A UPN 253 
X UPN 281 
mean of n = 22
Figure 1 Course of ABO antibody titers IgM (a) and IgG (b) after major 
ABO incompatible BMT. (a) shows the mean course of antibody titers 
(IgM) in 22 patients with timely recovery of donor erythropoiesis after 
major ABO incompatible BMT (bold line); the eight patients with delayed 
onset of erythropoiesis are shown separately; (b) shows the same course 
for IgG
patient.10 In a study by Gmtir et al11 three out of 15 major
patients, donor were still undetectable 2 ABO antibody titers in the recipient. In the study by Gmtir
months after BMT. Six out of eight patients developed the et alx 1 14 evaluable patients received an ABO incompatible 
clinical picture of PRCA lasting from 3.5 to 9 months after graft. Seven patients underwent large volume plasma 
BMT. Except for a transient positive direct antiglobulin test exchange and seven patients received an erythrocyte-
in UPN 70 no clinical or laboratory signs of hemolysis were depleted graft. recovery of erythropoiesis was
observed at the beginning of erythrocyte production in five observed in all but three patients who had received a red 
of the six PRCA patients. In one patient donor erythrocytes cell depleted graft. Jin et al2t> however found no difference 
were never detectable after BMT. UPN 83 had 0.22% of in erythrocyte transfusion requirements between recipients
Major ABO Incompatible Lymphocyte-Depleted BMT
BMAM Bär et al
of a red cell depleted graft and patients who had plasma marrow grafts, depleted of lymphocytes by counterflow 
exchange or immunoadsorption before major ABO incom- centrifugation, compared to recipients of unmanipulated 
patible BMT. Secondly, all our patients received a lympho- grafts. Serious morbidity usually did not occur and 
cyte-depleted graft in contrast to the patients reported in immunosuppressive intervention was only occasionally 
the literature. Earlier studies in our patient population necessary, 
showed that lymphocyte depletion of donor marrow 
resulted in a high incidence of mixed chimerism and per­
sistence of host lymphocytes.27,28 However, cytogenetic Acknowledgements
evaluation of blood and marrow was usually not performed 
before 6 months after BMT. In the major ABO incompat­
ible patients of the current study cytogenetic analysis of the 
blood was not performed. Cytogenetic analysis of the bone 
marrow 6 months after BMT showed no difference in 
mixed chimerism between the group with PRCA and with­
out PRCA (data not shown). This data suggests that mixed 
chimerism of the bone marrow does not play a major role 
in the development of PRCA.
CsA was given as immunoprophylaxis post-transplant in 
all patients reported in the literature who developed PRCA 
after major ABO incompatible BMT.10' 12,21,22,29-33 In these 
studies CsA was administered alone or in combination with 
prednisone or a short course of methotrexate (MTX). PRCA 
was never observed after the use of only MTX to prevent 
GVHD. CsA acts primarily as an immunosuppressive agent 
on T lymphocyte proliferation in response to primary anti­
gen stimulation. In the case of major ABO incompatibility 
T lymphocytes are re-exposed to the stimulating A or B 
antigens. In this setting CsA does not inhibit T lymphocyte 
proliferation. All our patients were treated with CsA. In 
one patient with PRCA (UPN 100) erythropoiesis began 
while CsA was still administered. In the other four patients 
erythropoiesis started 0.5, 1, 2 and 3 months after cessation 
of CsA according to the treatment protocol. In the three 
patients with PRCA described by Gmtir et alu erythropoi­
esis began during CsA treatment in one patient and 10 and 
83 days respectively after conclusion of CsA in two pati­
ents. Volin and Ruutu21 described one patient recovering 
from PRCA while still on CsA treatment. In the case study 
by Ohashi et al29 stopping CsA had no effect on the recov­
ery of PRCA. So, in our opinion CsA only plays a role in 
the possibility to develop PRCA after allogeneic BMT.
Treatment with corticosteroids for PRCA was not found 
to be beneficial.10,29,32 In our study UPN 162, 253 and 281 
received corticosteroids for GVHD without apparent effect 
on erythropoiesis. Corticosteroids were administered to 
UPN 70 4.5 months after BMT in an attempt to treat PRCA. 
No further erythrocyte transfusions were required. One 
month afterwards 36% erythrocytes of donor origin were 
present. Spontaneous recovery can not be excluded as anti- 
A antibody titers were clearly decreasing before cortico­
steroid treatment was started.
Treatment successes and failures in PRCA after BMT 
have been described with plasma exchange10,21,22,32 and 
erythropoietin (EPO).29,30,33 A patient described by Ohashi 
et al2i> did not respond to EPO alone but erythropoiesis 
began after the addition of methylprednisolone to EPO. 
Gamma globulins were not found to be beneficial in two 
case reports.29,33 In two cases of PRCA treatment with anti­
lymphocyte globulin resulted in restoration of erythropoi­
esis.22'31 Immunohematologic complications did not occur 
more frequently in recipients of major ABO incompatible
We thank J Boezeman and T de Boo for assistance in statistical 
analysis.
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